一窝小鸟
发表于 2025-3-26 23:33:38
978-3-319-34269-6Springer International Publishing Switzerland 2014
陈旧
发表于 2025-3-27 02:46:31
http://reply.papertrans.cn/95/9415/941434/941434_32.png
wall-stress
发表于 2025-3-27 08:45:52
http://reply.papertrans.cn/95/9415/941434/941434_33.png
无法解释
发表于 2025-3-27 12:27:30
http://reply.papertrans.cn/95/9415/941434/941434_34.png
expdient
发表于 2025-3-27 16:30:12
http://reply.papertrans.cn/95/9415/941434/941434_35.png
SPASM
发表于 2025-3-27 20:21:22
http://reply.papertrans.cn/95/9415/941434/941434_36.png
唠叨
发表于 2025-3-27 22:24:32
Outcome Measures in Rheumatoid Arthritis,stems. Hence, it is hard to develop single domain outcome measures for rheumatologic conditions as in hypertension (systolic and diastolic blood pressure), diabetes (hemoglobin A1C), or hypothyroidism (thyroid-stimulating hormone). For this reason, several composite outcome measures have been develo
Temporal-Lobe
发表于 2025-3-28 04:20:11
http://reply.papertrans.cn/95/9415/941434/941434_38.png
Incisor
发表于 2025-3-28 09:11:43
The Randomized Controlled Trial: Methodological Perspectives,an interventional study. We focus here on interventions by drugs, but much of what we discuss also applies to other types of interventions. A wide variety of topics is reviewed, such as the choice between the different RCT designs (parallel group, cross-over, adaptive designs, etc.), the importance
CAB
发表于 2025-3-28 13:43:13
Limitations of Traditional Randomized Controlled Clinical Trials in Rheumatology,er, clinical trials have many limitations, as is seen with every method in scientific research; these limitations may be classified as pragmatic or intrinsic. Pragmatic limitations of clinical trials in chronic rheumatic diseases include a relatively short time frame – often too short to recognize i